Multiple randomized controlled trials (RCTs) have shown that trastuzumab therapy improves patient outcomes, and consequently trastuzumab has become the standard treatment for HER2-positive breast cancer patients in both the neoadjuvant and metastatic settings [7, 8]. Here, ERBB2 is linked to breast cancer.